Close Menu
News JournosNews Journos
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
Editors Picks

Trump Administration Dismisses Nearly 400 Scientists from National Climate Report Team

April 29, 2025

JFK Assassination Files Set for Release Today, According to Trump

March 18, 2025

Police Investigate Vandalism Targeting Tesla Owners, Including Cybertruck

March 31, 2025

Republicans Divided Over Trump Proposal to Cut USAID and Public Broadcasting

July 10, 2025

Meta and Anduril Collaborate on VR/AR Project for U.S. Army

May 29, 2025
Facebook X (Twitter) Instagram
Latest Headlines:
  • Sarah Ferguson Cut Off by U.K. Charities Following Epstein Email Revelation
  • Travel Tips: Safeguarding Yourself from Fake Airline Wi-Fi Scams
  • Study Reveals 90% of Jimmy Kimmel’s Political Jokes Target Conservatives
  • Dua Lipa Parts Ways with Agent Amid Controversy Over Pro-Palestine Band Kneecap
  • Trump Claims Acetaminophen Use in Pregnancy Linked to Autism
  • President Erdoğan’s Speech Cut Short by Technical Issues
  • Trump Declares Antifa a Domestic Terrorist Organization in New Executive Order
  • Amazon on Trial for Allegedly Misleading Prime Membership Enrollment
  • Jimmy Kimmel Live! to Return After Weeklong Hiatus
  • Immigration Attorneys Address Trump’s Proposed $100,000 H-1B Fee
  • Dominican Republic Seizes Drugs After US Airstrike on Vessel
  • 2025 Fat Bear Week Voting Begins for Alaska National Park Contenders
  • Trump’s $100,000 Fee Impacts Top Global Talent Hubs
  • Fed Governor Advocates for Significant Key Interest Rate Reduction
  • Jimmy Kimmel Live Returns to ABC on Tuesday
  • Ohio Republicans Ramaswamy and Husted Announce Mutual Endorsements
  • Man Arrested for Aiming Laser Pointer at Trump’s Marine One
  • UK, Australia, and Canada Officially Recognize Palestinian State
  • Study Reveals iPhone Users More Susceptible to Online Scams Than Android Users
  • Cowboys’ George Pickens Reacts Emotionally on Bench During Game
Facebook X (Twitter) Instagram
News JournosNews Journos
Subscribe
Tuesday, September 23
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
News JournosNews Journos
You are here: News Journos » Politics » Trump Exempts Medicaid from Covering GLP-1s for Obesity, but Some States Move Forward
Trump Exempts Medicaid from Covering GLP-1s for Obesity, but Some States Move Forward

Trump Exempts Medicaid from Covering GLP-1s for Obesity, but Some States Move Forward

News EditorBy News EditorMay 20, 2025 Politics 6 Mins Read

In Charleston, South Carolina, patients are turning to Wegovy, an injectable drug designed for weight loss, amidst an evolving landscape of health insurance coverage for obesity treatments. The drug, part of a class known as GLP-1 agonists, has been hailed as a breakthrough for individuals struggling with obesity. However, accessibility remains a significant issue, with many insurers still classifying these medications as prohibitively expensive despite growing demand and positive patient outcomes. As more states begin to adopt coverage policies, the implications for public health and personal well-being are becoming increasingly evident.

Article Subheadings
1) Patient Experiences with Wegovy
2) Coverage Landscape for GLP-1 Agonists
3) Challenges in Accessing Treatment
4) Financial Implications
5) The Future of Obesity Treatment

Patient Experiences with Wegovy

One notable patient, Page Campbell, began using Wegovy upon her doctor’s recommendation before considering bariatric surgery. At 40 years old, a single mother of two, she expressed that her weight struggles had persisted for a long time, leading her to explore any available treatments. After approximately four weeks on Wegovy, Campbell reported no side effects, such as nausea or bowel issues, but admitted she was uncertain about her weight loss progress since she does not own a scale.

Confidence in the treatment’s efficacy was evident as Campbell emphasized her commitment to dietary changes and increased physical activity. “It’s going to work because I’m putting in the work,” she said, highlighting a broader trend among patients who view Wegovy not merely as a drug but as part of a lifestyle overhaul.

Coverage Landscape for GLP-1 Agonists

Wegovy is part of a new generation of medications, known scientifically as GLP-1 (glucagon-like peptide-1) agonists, which have transformed obesity management by providing a biochemical method of appetite regulation. As of late 2024, access to Wegovy expanded significantly in South Carolina, where the state’s Medicaid program began covering such medications. This marks a significant step, though concerns linger about coverage gaps across other states.

A report from a health information nonprofit highlighted that only 13 states were covering GLP-1s for Medicaid beneficiaries as of August 2024, with South Carolina being the 14th to join in November. This limited access restricts many patients who might benefit from such treatments, underscoring a growing divide in healthcare accessibility.

Challenges in Accessing Treatment

Despite the new coverage policies, accessing these treatments remains arduous for many patients. In South Carolina, potential beneficiaries face stringent prerequisites to qualify for Wegovy. For instance, they must show documented efforts toward weight loss over six months through prescribed dieting and counseling. Even with a firm approval, Campbell will need to prove a weight loss of at least 5% before her coverage is renewed, further complicating the treatment process.

According to Jeff Leieritz, spokesperson for the South Carolina Department of Health and Human Services, such high entry barriers might discourage eligible individuals from seeking assistance. Moreover, the irony lies in the fact that South Carolina’s obesity rates are starkly high, yet only a limited number of patients are expected to benefit from the coverage due to the criteria imposed.

Financial Implications

From a financial perspective, the implications of covering GLP-1s for health plans and patients are profound. The cost of Wegovy and similar medications frequently exceeds $1,000 per month, which makes long-term reliance on these drugs particularly challenging. Recent changes have seen a reduction in price, with Novo Nordisk, the manufacturer, cutting the retail price from $650 to $499. However, even these new prices are quite steep for regular consumers.

The financial strain on state healthcare budgets is illustrated by the decisions made in neighboring North Carolina, where cost assessments estimated that the state’s plan could be burdened by $1 billion over just six years. Consequently, the North Carolina State Health Plan opted to discontinue coverage of GLP-1s for state employees. This decision reflects the broader economic considerations that state governments must navigate when expanding coverage options.

The Future of Obesity Treatment

Looking forward, many health experts are lobbying for broader access to GLP-1s as a potential solution to the obesity epidemic. During an interview, Robert F. Kennedy Jr., Health and Human Services Secretary, mentioned the possibility of Medicare and Medicaid expanding coverage to include GLP-1s for obesity treatment if costs decrease sufficiently. “These are extraordinary drugs, and we’re going to reduce the cost,” he stated, signaling a potential shift in policy direction.

Although the current political landscape poses challenges to the implementation of additional coverage policies, public health experts continue to support initiatives aimed at tackling obesity comprehensively. Organizations in South Carolina have advanced an “Action Plan for Healthy Eating and Active Living” which emphasizes physical activities and nutritional education, yet converging narratives on medication’s role still need more robust inclusion in future strategies.

No. Key Points
1 Wegovy is an injectable drug that helps with weight loss and is part of the GLP-1 class of medications.
2 Access to GLP-1s is limited, with many insurance providers considering them too expensive to cover broadly.
3 Patients in South Carolina must meet strict criteria to gain Medicaid coverage for Wegovy.
4 The high financial costs of GLP-1s present significant barriers to access for many patients.
5 Future possibilities exist for expanding coverage of obesity treatments like GLP-1s through Medicare and Medicaid.

Summary

The evolving landscape of weight loss treatments, particularly with GLP-1 medications like Wegovy, highlights a crucial intersection of healthcare policy, patient experience, and public health. While steps have been taken to provide greater access in states like South Carolina, barriers remain for many individuals who could significantly benefit from these innovative drugs. Continuous advocacy for comprehensive coverage is essential as society looks to address the obesity crisis and improve the well-being of millions.

Frequently Asked Questions

Question: What are GLP-1 agonists?

GLP-1 agonists are a class of medications that mimic the action of the glucagon-like peptide-1 hormone, which is involved in appetite regulation and insulin signaling. These drugs are commonly used to treat obesity and diabetes.

Question: How does insurance coverage for Wegovy vary across states?

Insurance coverage for Wegovy and other GLP-1 medications varies widely between states. Some states have implemented Medicaid coverages, while others consider the drugs too costly, limiting access for eligible patients.

Question: What are some alternatives to pharmacological treatments for obesity?

Alternatives to pharmacological treatments include lifestyle changes such as diet modifications, increased physical activity, counseling, and surgical interventions like bariatric surgery, which can provide long-term weight loss solutions.

Bipartisan Negotiations Congressional Debates Covering Election Campaigns Executive Orders Exempts Federal Budget GLP1s Healthcare Policy House of Representatives Immigration Reform Legislative Process Lobbying Activities Medicaid move National Security Obesity Party Platforms Political Fundraising Presidential Agenda Public Policy Senate Hearings states Supreme Court Decisions Tax Legislation Trump Voter Turnout
Share. Facebook Twitter Pinterest LinkedIn Email Reddit WhatsApp Copy Link Bluesky
News Editor
  • Website

As the News Editor at News Journos, I am dedicated to curating and delivering the latest and most impactful stories across business, finance, politics, technology, and global affairs. With a commitment to journalistic integrity, we provide breaking news, in-depth analysis, and expert insights to keep our readers informed in an ever-changing world. News Journos is your go-to independent news source, ensuring fast, accurate, and reliable reporting on the topics that matter most.

Keep Reading

Politics

Trump Declares Antifa a Domestic Terrorist Organization in New Executive Order

6 Mins Read
Politics

Ohio Republicans Ramaswamy and Husted Announce Mutual Endorsements

6 Mins Read
Politics

Memorial Service Celebrates Legacy of Conservative Activist Charlie Kirk

6 Mins Read
Politics

Charlie Kirk’s Widow Takes Helm of Turning Point, Commits to Continuing His Mission

6 Mins Read
Politics

Trump Administration Threatens Lawsuits and Funding Cuts Over Migrant Detention in Democratic States

6 Mins Read
Politics

California GovernorSigns Law Prohibiting Law Enforcement from Wearing Face Coverings

6 Mins Read
Journalism Under Siege
Editors Picks

Dems Criticize Elon Musk and Melania Trump for Xenophobic Remarks

April 5, 2025

17 Family Members of Notorious Cartel Leader Allowed into U.S. Under Agreement with Mexico

May 14, 2025

Veterans Urge Trump to Honor Marine War Hero Overlooked by Biden for Medal of Honor

February 23, 2025

Trump Endorses Garbarino and Fellow House Republicans

May 26, 2025

Trump Advocates Gaza Ceasefire Amid Israeli Military Evacuations

June 29, 2025

Subscribe to News

Get the latest sports news from NewsSite about world, sports and politics.

Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

News

  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Money Watch

Journos

  • Top Stories
  • Turkey Reports
  • Health
  • Tech
  • Sports
  • Entertainment

COMPANY

  • About Us
  • Get In Touch
  • Our Authors
  • Privacy Policy
  • Terms and Conditions
  • Accessibility

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2025 The News Journos. Designed by The News Journos.

Type above and press Enter to search. Press Esc to cancel.

Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.
Go to mobile version